Have a feature idea you'd love to see implemented?
Let us know!
IMRX Immuneering Corp
Price (delayed)
$2.15
Market cap
$63.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.91
Enterprise value
$8.34M
Highlights
The debt has declined by 7% year-on-year
The gross profit has shrunk by 100% YoY
Immuneering's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of IMRX
Market
Valuations
Earnings
Shares outstanding
29.65M
Market cap
$63.75M
Enterprise value
$8.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.96
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$56.07M
EBITDA
-$55.32M
Free cash flow
-$51.12M
Per share
Balance sheet
Liquidity
EPS
-$1.91
Free cash flow per share
-$1.72
Book value per share
$2.24
Revenue per share
$0
TBVPS
$2.36
Total assets
$77.09M
Total liabilities
$10.78M
Debt
$4.31M
Equity
$66.31M
Working capital
$56.9M
Debt to equity
0.07
Current ratio
9.39
Quick ratio
8.81
Net debt/EBITDA
1
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-58.8%
Return on equity
-66%
Return on invested capital
-243.6%
Return on capital employed
-79.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMRX stock price
How has the Immuneering stock price performed over time
Intraday
-2.27%
1 week
-3.15%
1 month
-25.09%
1 year
-62.15%
YTD
-70.75%
QTD
-13.65%
Financial performance
How have Immuneering's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$60.47M
Net income
-$56.07M
Gross margin
N/A
Net margin
N/A
The gross profit has shrunk by 100% YoY
Immuneering's revenue has shrunk by 100% YoY
The operating income has declined by 9% year-on-year and by 2.4% since the previous quarter
The net income has declined by 8% year-on-year and by 3.5% since the previous quarter
Growth
What is Immuneering's growth rate over time
Valuation
What is Immuneering stock price valuation
P/E
N/A
P/B
0.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 2.1% since the previous quarter
Immuneering's equity has decreased by 42% YoY and by 16% from the previous quarter
IMRX's P/B is 35% less than its last 4 quarters average of 1.5
Immuneering's revenue has shrunk by 100% YoY
Efficiency
How efficient is Immuneering business performance
IMRX's return on invested capital is down by 44% year-on-year and by 9% since the previous quarter
The ROE has contracted by 41% YoY and by 18% from the previous quarter
The ROA has declined by 38% year-on-year and by 16% since the previous quarter
Dividends
What is IMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMRX.
Financial health
How did Immuneering financials performed over time
The quick ratio has plunged by 56% YoY and by 36% from the previous quarter
The current ratio has dropped by 54% year-on-year and by 35% since the previous quarter
The debt is 93% smaller than the equity
IMRX's debt to equity has surged by 75% year-on-year and by 17% since the previous quarter
Immuneering's equity has decreased by 42% YoY and by 16% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.